Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 40 results for barrett's oesophagus

  1. Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management (NG231)

    This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques. It aims to improve outcomes by ensuring the most effective investigations and treatments are used.

  2. Gastro-oesophageal reflux, including Barrett's oesophagus

    All NICE products on gastro-oesophageal reflux, including barrett's oesophagus. Includes any guidance, advice and quality standards.

  3. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)

    This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.

  4. Balloon cryoablation for Barrett's oesophagus

    Awaiting development [GID-IPG10413] Expected publication date: TBC

  5. Narrow band imaging for Barrett's oesophagus (MIB179)

    NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .

  6. Photodynamic therapy for Barrett's oesophagus (IPG350)

    Evidence-based recommendations on photodynamic therapy for Barrett's oesophagus. This involves using a light-activated drug (called a photosensitising agent) with a laser to destroy the abnormal cells and to promote the growth of healthy cells.

  7. Epithelial radiofrequency ablation for Barrett's oesophagus (IPG344)

    Evidence-based recommendations on epithelial radiofrequency ablation for Barrett's oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy cells.

  8. Balloon cryoablation for Barrett's oesophagus (IPG682)

    Evidence-based recommendations on balloon cryoablation for Barrett’s oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.

  9. Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia (IPG496)

    Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.

  10. Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)

    This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  11. Cytosponge for detecting abnormal cells in the oesophagus (MIB240)

    NICE has developed a medtech innovation briefing (MIB) on Cytosponge for detecting abnormal cells in the oesophagus .

  12. Endoscopic treatments: For adults with Barrett's oesophagus with dysplasia, what is the effectiveness of different endoscopic ablation techniques alone or in combination with endoscopic resection?

    NG231/04A Question Endoscopic treatments: For adults with Barrett's oesophagus with dysplasia, what is the effectiveness of different...

  13. Oesophago-gastric cancer: assessment and management in adults (NG83)

    This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.